Tempus AI Stock Slumps 0.21% as $310M Trading Volume Lands 407th in Market Activity Amid Profitability Struggles and Tech-Driven Healthcare Gambits

Market Snapshot

On March 4, 2026, Tempus AI (TEM) closed with a 0.21% decline, reflecting modest weakness in its stock price. The company’s trading volume reached $0.31 billion, placing it at the 407th position in market activity for the day. While the decline was relatively small, it marked a continuation of a broader trend of volatility, as evidenced by the stock’s 52-week range of $36.22 to $104.32. The drop followed mixed signals from recent earnings reports and analyst forecasts, which highlighted both growth in revenue and persistent challenges in profitability.

Key Drivers

The recent performance of Tempus AI is shaped by a combination of financial underperformance, strategic initiatives, and analyst sentiment. Despite achieving a positive adjusted EBITDA for the first time in Q3 2025—driven by revenue growth of $334.2 million, which exceeded forecasts—ongoing negative earnings per share (EPS) and high operating expenses remain significant headwinds. The company reported a Q3 2025 EPS of -$0.11, an improvement from the -$0.18 forecast, but its net income margin remains negative at -14.75% for the same period. This financial strain is compounded by operating income declines in recent quarters, such as the -$60.444 million reported in Q2 2025, reflecting challenges in scaling profitability despite revenue growth.

A critical factor influencing market sentiment is Tempus AI’s strategic acquisition of Paige.AI, aimed at enhancing its digital pathology capabilities. The move has bolstered growth in key segments, including a 33% increase in genomics and 37% in hereditary testing. However, integration risks and the high costs associated with expanding AI-driven diagnostics have raised concerns about near-term profitability. Analysts from Morgan Stanley and Mizuho have highlighted these risks, though they remain optimistic about the company’s long-term potential as a technology-driven healthcare player. CEO Eric Lefkofsky’s vision of positioning Tempus as a tech-centric firm, despite continued negative EPS forecasts through FY 2026, has drawn both cautious optimism and skepticism.

Analyst activity further underscores the mixed outlook. Over the past six months, five analysts revised earnings forecasts upward, with price targets ranging from $59 to $105. Morgan Stanley maintained a “Buy” rating with a $70 target, while Stifel and JPMorgan held “Hold” positions. The divergence in analyst sentiment reflects uncertainty about Tempus AI’s ability to sustain revenue growth while reducing operating losses. For instance, the company’s operating expenses in Q3 2025 totaled $270.386 million, a 6.1% increase from the prior quarter, outpacing revenue growth and squeezing margins.

Challenges such as regulatory hurdles for new product submissions and intense competition in the AI diagnostics market also weigh on the stock. Despite achieving a 27% year-over-year revenue increase in Q1 2026 to $367.2 million, the company’s EBITDA margin remains weak at -5.56%. These factors have led to downward revisions in some price targets, as seen with TD Cowen’s downgrade in October 2025. Nevertheless, the recent analyst activity—particularly the “Buy” ratings from firms like Canaccord Genuity and Needham—suggests confidence in Tempus AI’s ability to leverage its data assets and AI capabilities for future growth.

The broader market context includes a focus on long-term value creation. While the stock’s 0.21% decline on March 4 may reflect short-term profit-taking or caution ahead of the May 2026 earnings report, the company’s ambitious growth targets and strategic bets on AI-driven healthcare position it for potential upside. Analysts’ emphasis on Tempus AI’s “tech-oriented” identity, despite current financial metrics, highlights a belief in its ability to transform its business model as AI adoption in healthcare accelerates. However, investors will likely remain cautious until the company demonstrates consistent profitability and effectively integrates acquisitions like Paige.AI into its core operations.